KQ-2003 CAR-T Cell Therapy for Relapsed or Refractory Multiple Myeloma
KQ-2003 CAR-T Cell Therapy for Relapsed or Refractory Multiple Myeloma
Will this trial show a positive result on objective response rateOutcome measureObjective Response Rate (ORR)Objective response rate is the share of patients whose tumors shrink by a predefined amount. It is useful for early signals and accelerated approval settings, but it is more surrogate than survival outcomes.ClinicalTrials.gov outcome?
Paper Trading
Create account to tradeMultiple Myeloma
Multiple myeloma is a blood cancer of plasma cells that can damage bones, kidneys, and immunity. The first endpoint checks dose safety, because severe side effects can mean hospital care or stopping treatment.